(June 2017)

Dupilumab is an interleukin (IL)-4 receptor alpha antagonist approved by the US Food and Drug Administration (FDA) for adults with moderate to severe atopic dermatitis not adequately controlled with topical therapies. In a phase III trial of over 700 patients with moderate to severe atopic dermatitis and inadequate response to topical corticosteroids, one year of treatment with dupilumab improved symptoms relative to placebo. All patients received topical corticosteroids or topical calcineurin inhibitors. These results support the use of dupilumab for the long-term treatment of moderate to severe atopic dermatitis when topical therapies alone are insufficient and other systemic treatments are contraindicated.

Lancet. 2017;389(10086):2287

Comment: This is an exciting development for the treatment of moderate to severe eczema for which there was no adequate treatment options. This has been a life changing option for severe adult patients. Studies are now underway to seek approval for use in children under the age of 18.

Adult and Pediatric Dermatology
4601 W. 109th St., Suite 116  •  Overland Park, Kansas 66211  •  913-469-1115